| Biotechnology Industry | Healthcare Sector | Mr. Guoqiang Ke CEO | SSE Exchange | CNE100002RG2 ISIN |
| CN Country | 45,466 Employees | 26 Jun 2026 Last Dividend | 9 Jun 2023 Last Split | - IPO Date |
DaShenLin Pharmaceutical Group Co., Ltd. is a comprehensive entity in the pharmaceutical industry within China, focusing on the manufacturing, wholesale, and retail sectors. Since its establishment in 1999, the company has developed a solid foundation in its field, operating out of Guangzhou, China. Its business encompasses a broad spectrum of pharmaceutical products, catering to various healthcare needs through both traditional Chinese and modern Western medicine approaches.
DaShenLin offers a variety of patented pharmaceutical products that include both traditional Chinese medicines and Western-style drugs. By providing an array of treatments, they cater to a wide range of medical conditions, ensuring access to quality healthcare solutions.
This line of products emphasizes the importance of traditional Chinese medicinal practices, offering high-quality ginseng tonics and a selection of herbal pieces. These are key ingredients for many traditional treatments, known for their health benefits and healing properties.
The company extends its offerings to include health care products aimed at enhancing general well-being and preventing illnesses. These products are designed to meet the wellness needs of the modern consumer, promoting a healthy lifestyle.
DaShenLin provides a range of medical equipment, supporting healthcare facilities and professionals in delivering medical services. This category includes items essential for diagnosis, treatment, and patient care, ensuring the availability of high-quality medical apparatus.
Expanding beyond the pharmaceutical and medical sectors, the company also offers a selection of other commodities. This diversity reflects DaShenLin’s commitment to catering to the broader needs of their customers, providing more than just healthcare products.